Experiences with
Acalabrutinib574 public posts
Want to take advantage of all our features? Just log in!
or
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Estimated 36-month overall survival was 94.1% with acalabrutinib–venetoclax, 87.7% with acalabrutinib–venetoclax–obinutuzumab, and 85.9% with chemoimmunotherapy.
Chemo-free treatment with acalabrutinib can benefit CLL/SLL patients never treated before: a plain language summary of the ELEVATE-TN study
[i][/i]
[i]Patients were divided into 3 groups:[/i]
[i] 1) acalabrutinib alone[/i]
[i] 2) acalabrutinib plus obinutuzumab, a monoclonal antibody[/i]
[i]3) the usual chemoimmunotherapy treatment (chlorambucil plus a monoclonal antibody).
New Greek consensus statement for the treatment of chronic lymphocytic leukemia
No significant difference was seen in terms of PFS between Ibrutinib monotherapy and Ibrutinib - Rituximab in the ALLIANCE trial.¹⁵ In the ELEVATE TN trial, at 6 years of follow-up, PFS was significantly longer in patients treated with Acalabrutinib plus Obinutuzumab versus Acalabrutinib, while